NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Kyverna Therapeutics, Inc. (KYTX) Stock Analysis

Kyverna Therapeutics, Inc. (KYTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

KYTX

$8.25

−$0.10 (−1.20%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare KYTX with… →

KYTX Key Statistics

As of Sep 4, 2026
Trading
Open
$8.26
Previous Close
$8.35
Day's Range
8.20–8.38
52-Week Range
3.72–13.67
Volume
500.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.99
Valuation
Market Cap
$510.21M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.92
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$161.31M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
61.84M
1-Year Return
+127.27%
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
992.61K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

KYTX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−12.23%
2025+151.34%
2024 (partial year)−87.57%

As of September 4, 2026.

KYTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$161.31M—
2024$0.00−$127.48M—
2023$0.00−$60.37M—
2022$7.03M−$28.89M−411.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$169.83M−$161.31M—
2024$0.00—−$142.60M−$127.48M—
2023$0.00—−$62.41M−$60.37M—
2022$7.03M—−$29.38M−$28.89M−411.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

KYTX Valuation vs Biotechnology Median

Median of 656 stocks
MetricKYTXBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Kyverna Therapeutics, Inc. (KYTX) carries a market capitalisation of $510.21M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 149.

Over the past 52 weeks the price has ranged from $3.72 to $13.67. The most recent close on file for KYTX is $8.25, dated September 4, 2026. That is −$0.10 (−1.20%) against the previous close. The latest close sits 121.95% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $161.31M. Profit margin runs at 0%. Trailing earnings per share are −2.92.

Across the 4 fiscal years on file, revenue moves from $7.03M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year price return is +127.27%. The stored price history starts on February 9, 2024, and the total return since then is −72.59%. The reported beta is 1.99. Annualized volatility over the trailing 2 years is 96.44%.

Growth & Income

The record shows no dividend for KYTX.

2026 is still running; the price is −12.23% year to date. The record holds one complete calendar year, 2025, which returned +151.34%.

Peer Comparison

Kyverna Therapeutics, Inc. (KYTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Kyverna Therapeutics, Inc. KYTX $510.21M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Kyverna Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Visit website →